Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Thyrotropinoma with silent somatotroph and lactotroph adenoma during pregnancy.
Wu YF, Ng HY, Namboodiri D, Lewis D, Davidson A, Champion B, Preda V.
Endocrinol Diabetes Metab Case Rep. 2022 Sep 1;2022:21-0194. doi: 10.1530/EDM-21-0194. Online ahead of print.
Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W, Jiang S, Zhou P.
Endocrine. 2019 Nov;66(2):310-318. doi: 10.1007/s12020-019-02029-1. Epub 2019 Jul 31.
Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion.
Serri O.
Clin Endocrinol (Oxf). 1987 Dec;27(6):675-82. doi: 10.1111/j.1365-2265.1987.tb02951.x.
Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.
Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P, Enjalbert A.
J Clin Endocrinol Metab. 1996 Sep;81(9):3390-6. doi: 10.1210/jcem.81.9.8784102.
Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
Kleinschmidt-DeMasters BK.
J Neuropathol Exp Neurol. 2024 Sep 1;83(9):708-721. doi: 10.1093/jnen/nlae050.
GH-Secreting Adenoma or Tumor? Issues in Pituitary Neoplasms Nomenclature, Classification, and Characterization.
Guaraldi F, Di Sciascio L, Shwaish TZT, Zoli M, Mazzatenta D, Asioli S.
Front Horm Res. 2024;55:119-132. doi: 10.1159/000539946.
Clonal origin of pituitary adenomas.
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S.
J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33. doi: 10.1210/jcem-71-6-1427.
Outcome of giant pituitary tumors requiring surgery.
Gaillard S, Adeniran S, Villa C, Jouinot A, Raffin-Sanson ML, Feuvret L, Verrelle P, Bonnet F, Dohan A, Bertherat J, Assié G, Baussart B.
Front Endocrinol (Lausanne). 2022 Aug 29;13:975560. doi: 10.3389/fendo.2022.975560. eCollection 2022.
Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
Nf L, Ai M.
Pituitary. 2023 Apr;26(2):182-186. doi: 10.1007/s11102-023-01312-9. Epub 2023 Apr 29.
Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case report.
Brunner M, Meylan-Merlini J, Muriset M, Oreshkov S, Messina A, Messerer M, Daniel R, Hewer E, Brouland JP, Santoni F.
BJC Rep. 2025 Jun 16;3(1):43. doi: 10.1038/s44276-025-00155-0.
